Theramex And Alkem’s Enzene Ally On Denosumab
Women’s Health Firm Gains Rights To Prolia Biosimilar In Europe And Australia
Executive Summary
Women’s health specialist Theramex has struck a deal with Alkem’s Enzene Biosciences biotech subsidiary to gain rights to Enzene’s proposed denosumab biosimilar version of Prolia in Europe and Australia.
You may also be interested in...
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Alkem Looks To Biosimilars With Enzene’s Teriparatide In India
With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.
Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.